- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04129255
Octreotide LAR in the Induction of Immunologic Response in NENs Patients (CSMS99)
IMMUNeOCT Study: Octreotide LAR in the Induction of Immunologic Response in Patient With Neuroendocrine Tumors: an Interventional Pharmacological Study
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy
- Istitute Nazionale Tumori - Fondazione G. Pascale
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent prior to initiation of any study-specific procedures or treatment, as confirmation of the patients awareness and willingness to comply with the study requirements.
- Patients ≥18 years of age.
- Patients with histologically confirmed well and moderately differentiated Neuroendocrine Tumors with Ki67 ≤ 20% (Ki67 must be quantified in percentage) and candidates for treatment with octreotide.
- ECOG performance status (PS) of 0-2.
- At least 28 days since prior the last radiation therapy or surgery.
- Estimated life expectancy of ≥12 weeks.
Exclusion Criteria:
- Patients < 18 years of age.
- According to the current SmPC of the prescribed drug agent.
- Previuos treatment with octreotide.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would prevent the patient from meeting the study requirements.
- Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry.
- Patients who are treated with any medicinal product that contraindicates the use of the study drug, may interfere with the planned treatment, affects patient compliance or puts the patient at high risk for treatment-related complications.
- Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start. Women of childbearing potential (defined as inferior to 2 years after last menstruation and not surgically sterile) not using effective, non hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
- Patients with meningeal carcinomatosis
- Patients with known positive HIV status
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)
OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
|
administration every 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploring the changes in immune-regulatory cells induced by OCT LAR
Time Frame: 6 months
|
The primary objective of the project is to evaluate changes in immune-regulatory cells induced by OCT LAR from baseline to month 6.
Therefore, we will observe the impact of OCTREOTIDE LAR on the immune response by studying T-Reg and MDSC and the immunoregulatory cell population in peripheral blood of patients with neuroendocrine tumors G1 / G2 treated with OCT LAR.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcome
Time Frame: 3 months (PFS - ORR)
|
Objective response rate according to RECIST. Progression-free survival (PFS), defined as the time (days) from start date of octreotide to date of first documented disease progression or death due to any cause, if death occurs before progression is documented. Progression-free survival as the time (days) from start date of OCT to date of first PD or death due to any cause; Safety :number of patients presenting AE during treatment and observation period (CTCAE v.4) |
3 months (PFS - ORR)
|
safety assessment
Time Frame: 1 month (safety)
|
Safety profile according to CTCAE criteria
|
1 month (safety)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Salvatore Tafuto, MD, NCI Naples
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Physiological Effects of Drugs
- Antineoplastic Agents
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Octreotide
- Somatostatin
Other Study ID Numbers
- IMMUNeOCT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Francesco De CobelliCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on Octreotide Acetate
-
Azidus BrasilSuspended
-
NovartisCompletedDiabetic RetinopathyUnited States
-
Endo PharmaceuticalsCompleted
-
Novartis PharmaceuticalsTerminated
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
University College, LondonNational Institute for Health Research, United KingdomActive, not recruitingLiver Transplantation | Renal FailureUnited Kingdom
-
Lexicon PharmaceuticalsCompletedDrug InteractionsUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedColorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation EnteritisUnited States
-
Novartis PharmaceuticalsTerminated
-
Debiopharm International SAActive, not recruitingAcromegaly | GEP-NETUnited Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel